View Full Table | Close Full ViewTable 1.

Intercept and slope of chemistry biomarkers and bodyweight change with SE for the correlation between meloxicam (MEL) plasma concentration and the outcome variables

 
log MEL
Parameter Intercept Slope gradient estimate SE P-value
Bodyweight, kg 354.34 0.08 0.30 0.78
Log cortisol, ng/mL 37.19 –1.51 0.47 0.0017
Substance P, pg/mL 26.06 0.16 0.78 0.89
Plasma protein, g/dL 6.96 –0.01 0.01 0.32
Fibrinogen, mg/dL 454.96 3.03 3.76 0.42
Haptoglobin-matrix metalloproteinase-9 complexes, ng/mL 1.42 –0.02 0.05 0.74
Total carbon dioxide, mM 24.91 –0.01 0.06 0.90
Tumor necrosis factor-alpha, pg/mL 168.05 0.09 1.91 0.96



View Full Table | Close Full ViewTable 2.

Comparison between the least squares (LS) means ± SE serum chemistry biomarkers at 0, 24, and 144 h after treatment (trt) with 1 mg/kg meloxicam (MEL) or a placebo (CONT) before transportation

 
Time, h
P-values
0
24
144
Parameter Normal range Trt group LS means ± SE LS means ± SE LS means ± SE Trt Time Time × trt
Plasma protein, g/dL 6.9–7.7 CONT 7.02a ± 0.07 7.40b ± 0.07 7.00a ± 0.07 0.32 <0.0001 0.18
MEL 7.02a ± 0.07 7.32b ± 0.07 6.88b ± 0.07
Total carbon dioxide, mM CONT 22.77a ± 0.33 24.98b ± 0.34 0.51 <0.0001 0.77
MEL 22.43a ± 0.33 24.81b ± 0.33
Fibrinogen, mg/dL 100–500 CONT 438.11 ± 24.68 462.39 ± 24.68 483.8 ± 25.09 0.41 0.173 0.30
MEL 426.23 ± 24.30 477.62 ± 24.12 433.85 ± 25.54
a,bDifferent superscripts indicate significant differences between timepoints in a row after transportation (P < 0.05).



View Full Table | Close Full ViewTable 3.

Comparison between the least squares (LS) means ± SE of red blood cell parameter data at 0, 24, and 144 h after treatment (trt) with 1 mg/kg meloxicam (MEL) or a placebo (CONT) before transportation at 0 h, after transportation at 24 h, and at 144 h thereafter

 
Parameter Normal range Trt group Time, h
P-values
0
24
144
Trt Time Time × trt
LS means ± SE LS means ± SE LS means ± SE
Red blood cell, 103 cells/μL 5.0–10.0 CONT 8.47a ± 0.14 8.59a ± 0.14 8.19b ± 0.14 0.13 <0.0001 0.38
MEL 8.80a ± 0.14 8.79a ± 0.14 8.50b ± 0.14
Hemoglobin, g/dL 8.0–15.0 CONT 11.75a ± 0.15 12.00b ± 0.15 11.27c ± 0.15 0.98 <0.0001 0.17
MEL 11.83a ± 0.15 11.85a ± 0.15 11.33b ± 0.15
Hematocrit, % 24.0–46.0 CONT 33.12a ± 0.43 33.94b ± 0.43 31.90c ± 0.44 1.00 <0.0001 0.20
MEL 33.42a ± 0.42 33.52a ± 0.42 32.04b ± 0.43
Mean corpuscle volume, fL 40.0–60.0 CONT 39.27a ± 0.45 39.69b ± 0.45 39.15a ± 0.45 0.05 <0.0001 0.20
MEL 38.17a ± 0.44 38.33a ± 0.44 37.91b ± 0.44
Mean corpuscle hemoglobin, Pg 11.0–17.0 CONT 13.95a ± 0.18 14.03a ± 0.18 13.83b ± 0.18 0.05 <0.0001 0.61
MEL 13.51ab ± 0.18 13.55a ± 0.18 13.41b ± 0.18
Mean corpuscle hemoglobin concentration, g/dL 30.0–36.0 CONT 35.52 ± 0.16 35.35 ± 0.16 35.35 ± 0.17 0.87 0.46 0.70
MEL 35.40 ± 0.16 35.37 ± 0.16 35.37 ± 0.17
Red blood cell distribution width, % 8.0–15.0 CONT 18.78a ± 0.27 18.42b,x ± 0.27 18.97a ± 0.27 0.14 <0.0001 0.07
MEL 19.00 ± 0.27 18.95y ± 0.27 19.20 ± 0.27
a,b,cDifferent superscripts indicate significant differences between timepoints in a row after transportation (P < 0.05).
x,yDifferent superscripts indicate significant differences between treatment groups in the related CONT and MEL columns after transportation (P < 0.05).



View Full Table | Close Full ViewTable 4.

Comparison between the least squares (LS) means ± SE of white blood cell parameter data at 0, 24, and 144 h after treatment (trt) with 1 mg/kg meloxicam (MEL) or a placebo (CONT) before transportation at 0 h, after transportation at 24 h, and at 144 h thereafter

 
Time, h
P-values
0
24
144
Trt Time Time × trt
Parameter Normal range Trt group LS means ± SE LS means ± SE LS means ± SE
Platelet, 103 cells/μL 100–800 CONT 389.47a ± 23.25 392.62a ± 23.25 534.26b ± 23.57 0.81 <0.0001 0.14
MEL 395.53a ± 22.80 409.78a ± 22.80 490.79b ± 23.75
Neutrophil, 103 cells/μL 0.6–4.0 CONT 1.89a ± 0.23 3.88b,x ± 0.23 2.54c ± 0.24 0.10 <0.0001 0.10
MEL 1.75a ± 0.23 3.18b,y ± 0.23 2.42c ± 0.24
Lymphocyte, 103 cells/μL 2.5–7.5 CONT 7.32a,x ± 0.41 6.31b ± 0.41 5.69c ± 0.41 0.05 <0.0001 0.29
MEL 6.43a,y ± 0.41 5.73b ± 0.41 5.20c ± 0.41
Neutrophil:lymphocyte ratio, 103 cells/μL CONT 4.90a ± 0.70 3.16b ± 0.70 2.41b ± 0.71 0.31 <0.0001 0.47
MEL 4.51a ± 0.70 2.26b ± 0.69 2.51b ± 0.71
Monocyte, 103 cells/μL 0.03–0.85 CONT 0.39a ± 0.03 0.55b,x ± 0.03 0.45a ± 0.03 0.27 0.0001 0.04
MEL 0.38a ± 0.03 0.44ab,y ± 0.03 0.47b ± 0.03
Basophils, 103 cells/μL 0–0.2 CONT 0.08 ± 0.01 0.08 ± 0.01 0.07 ± 0.01 0.08 0.8336 0.11
MEL 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01
a,b,cDifferent superscripts indicate significant differences between timepoints in a row after transportation (P < 0.05).
x,yDifferent superscripts indicate significant differences between treatment groups in the related CONT and MEL columns after transportation (P < 0.05).



View Full Table | Close Full ViewTable 5.

Intercept and slope of hematological biomarkers with SE for the correlation between meloxicam (MEL) plasma concentration and the outcome variables

 
Log MEL
Parameter Intercept Slope gradient estimate SE P-value
Basophils, 103 cells/μL 0.08 0.00 0.00 0.03
Neutrophil, 103 cells/μL 2.58 –0.07 0.03 0.04
Hemoglobin, g/dL 11.34 –0.03 0.02 0.06
Hematocrit, % 32.08 –0.09 0.05 0.07
Red blood cell distribution width, % 19.05 0.03 0.02 0.07
White blood cell, 103 cells/μL 9.05 –0.07 0.05 0.12
Red blood cell, 106 cells/μL 8.37 –0.02 0.01 0.20
Monocyte, 103 cells/μL 0.47 –0.01 0.00 0.27
Mean corpuscle volume, fL 38.52 –0.02 0.02 0.27
log mean platelet volume, fL 2.07 0.01 0.01 0.30
Neutrophil:lymphocyte ratio, 103 cells/μL 2.54 –0.05 0.06 0.42
Platelet, 103 cells/μL 508.83 2.78 3.60 0.44
Mean corpuscle hematocrit, g/dL 35.35 0.01 0.02 0.73
Mean corpuscle hemoglobin, pg 13.61 0.00 0.01 0.79
Lymphocyte, 103 cells/μL 5.45 –0.01 0.03 0.80